Interleukin-2 induces chemotactic deficiency in patients with onco hematologic malignancies and autologous bone marrow transplantation.
Unusual gram positive bacteremia has been reported in non granulopenic patients receiving recombinant human interleukin-2 (IL-2) suggesting a beneficial effect of anti gram positive prophylaxis in such patients. We report here studies on granulocyte functions examined during the course of high dose IL-2 therapy (16 to 24 million IU/m2/days for 11 to 18 days) administered during a period of 35 days in 14 patients including 4 solid tumors, 5 chronic myeloid leukemias, 4 recipients of autologous bone marrow transplant (ABMT) and 1 recipient of syngeneic bone marrow transplant. Neutrophils functions were studied before IL-2 administration (d 0), after the first cycle (d 8) and after the third cycle (d 36). Nylon fiber adherence, superoxide production, random migration, phagocytosis, nitroblue tetrazolium reduction, lysozyme and elastase release were not impaired significantly throughout therapy. However N-Formyl-Methionyl-Leucyl-Phenylalanine (FMLP) stimulated chemotaxis of granulocytes, normal before therapy, was significantly impaired as early at d 8 and severely inhibited at d 36 (p less than 0.001). Three septicemia, one corynebacteria parvum septicemia and two gram-negative septicemia despite normal neutrophil counts and oxacillin or Penicillin G plus Pefloxacin prophylaxis, occurred among the 14 patients studied. Although neutrophil functions were not more depressed in transplanted patients than in the other non transplanted patients, special attention should be paid to such patients in whom delayed immune reconstitution could increase the risk of sepsis.
Stoppa
A M
AM
Department of Haematology, Institut Paoli Calmettes, Marseille, France.
Fossat
C
C
Blaise
D
D
Viens
P
P
Brandely
M
M
Pourreau
C N
CN
Sainty
D
D
Novakovitch
G
G
Miquel
M
M
Juhan-Vague
I
I
D000328:Adult; D016026:Bone Marrow Transplantation / Q000502:physiology*; D001943:Breast Neoplasms / Q000097:blood* / Q000601:surgery / Q000628:therapy*; D002448:Cell Adhesion / Q000187:drug effects; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D005260:Female; D006098:Granulocytes / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood* / Q000601:surgery / Q000628:therapy*; D008297:Male; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009362:Neoplasm Metastasis; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology*; D009580:Nitroblue Tetrazolium / Q000378:metabolism; D010587:Phagocytosis / Q000187:drug effects; D012509:Sarcoma / Q000097:blood* / Q000601:surgery / Q000628:therapy*; D013481:Superoxides / Q000097:blood; D014182:Transplantation, Autologous
D007376:Interleukin-2; D013481:Superoxides; D009580:Nitroblue Tetrazolium; D009240:N-Formylmethionine Leucyl-Phenylalanine